Drone strike devastates Indian‑origin pharmaceutical complex
New Delhi. A Russian‑launched drone bombed the Kusum Group’s manufacturing site in Sumy, Ukraine, reducing the main structure to rubble, killing an engineer and wounding several staff members. The assault struck the plant’s engineering wing repeatedly, triggering an immediate evacuation.
Initial estimates place the financial hit at around Rs 400 crore, though the company says a comprehensive audit is still pending. The extensive destruction means the facility will likely stay shut for an undefined period.
Indian heritage, Ukrainian operations
The Kusum Group entered Ukraine in 1994 as a distributor of Indian medicines. By 2009 it had erected a full‑scale production complex in Sumy, complementing its 2007 manufacturing base in India. Today the conglomerate produces more than 50 generic drugs, supplying Ukraine, Uzbekistan, Kazakhstan and the Philippines, and markets itself as a Ukrainian pharma player with Indian roots.
Production persisted through war – until now
Despite the ongoing conflict, the Sumy plant continued to manufacture medicines for local and regional patients. The latest drone attack, however, has forced a halt to operations and prompted the group to consider relocating vulnerable lines to its Indian facilities.
Ukrainian President Volodymyr Zelenskyy condemned the strike, confirming that a drone barrage targeted the pharmaceutical complex and resulted in a death. The event highlights the growing peril facing civilian and commercial sites in war zones.
Broader implications
The loss of the Sumy plant threatens the supply of essential generic drugs in the region and raises concerns about the robustness of cross‑border supply chains amid armed conflict. A detailed assessment will gauge the true economic and operational impact on the Indian‑linked conglomerate.
